tiprankstipranks
Advertisement
Advertisement

OTLK Stock Latest News

Outlook Therapeutics downgraded to Neutral from Buy at BTIG
The FlyOutlook Therapeutics downgraded to Neutral from Buy at BTIG
5d ago
OTLK
Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)
PremiumThe Fly
Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)
8d ago
OTLK
Outlook Therapeutics Launches New $100M ATM Offering
PremiumCompany Announcements
Outlook Therapeutics Launches New $100M ATM Offering
9d ago
8K
OTLK
OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
11d ago
OTLK
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/11/26?
PremiumMarket News
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/11/26?
12d ago
MXL
RXT
Outlook Therapeutics Announces New Equity Financing Transaction
PremiumCompany AnnouncementsOutlook Therapeutics Announces New Equity Financing Transaction
30d ago
8K
OTLK
Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering
Premium
The Fly
Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering
1M ago
OTLK
Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug
Premium
Company Announcements
Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug
1M ago
8K
OTLK
Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA
PremiumThe Fly
Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA
1M ago
OTLK
Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics
PremiumRatings
Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics
1M ago
OTLK
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
PremiumCompany Announcements
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
2M ago
8K
OTLK
Outlook Therapeutics submits formal dispute resolution request to FDA
PremiumThe Fly
Outlook Therapeutics submits formal dispute resolution request to FDA
2M ago
OTLK
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
PremiumCompany AnnouncementsOutlook Therapeutics Completes Dilutive Equity Offering With Warrants
2M ago
8K
OTLK
Outlook Therapeutics announces common stock, warrant offering, no amount given
Premium
The Fly
Outlook Therapeutics announces common stock, warrant offering, no amount given
2M ago
OTLK
Outlook Therapeutics Refinances Debt, Extends Note Maturities
Premium
Company Announcements
Outlook Therapeutics Refinances Debt, Extends Note Maturities
2M ago
8K
OTLK
Outlook Therapeutics announces $18.4M non-convertible note financing
PremiumThe Fly
Outlook Therapeutics announces $18.4M non-convertible note financing
2M ago
OTLK
Outlook Therapeutics Announces Board Resignation and Size Reduction
PremiumCompany Announcements
Outlook Therapeutics Announces Board Resignation and Size Reduction
2M ago
8K
OTLK
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
PremiumThe Fly
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
2M ago
OTLK
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
PremiumCompany Announcements
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
2M ago
8K
OTLK
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval
PremiumCompany AnnouncementsOutlook Therapeutics advances FDA dialogue on ONS-5010 approval
3M ago
8K
OTLK
Outlook Therapeutics provides update following FDA meeting on ONS-5010
Premium
The Fly
Outlook Therapeutics provides update following FDA meeting on ONS-5010
3M ago
OTLK
Outlook enters distribution agreement for sale of Lytenava in Switzerland
Premium
The Fly
Outlook enters distribution agreement for sale of Lytenava in Switzerland
3M ago
OTLK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >